Evidence map›Paper›PMID 36508875›Full record

ArticleNeoplasia (New York, N.Y.)2023

Proteomic profiling of canine fibrosarcoma and adjacent peritumoral tissue.

Erin Beebe, Amiskwia Pöschel, Laura Kunz, Witold Wolski, Zahra Motamed, Daniela Meier, Franco Guscetti, Mirja C Nolff, Enni Markkanen

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Journal of proteome research · 2025
    Article
  5. Evaluation of a targeted anti-αEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Erin BeebeInstitute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, 8057 Zürich, Switzerland.
Amiskwia PöschelInstitute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, 8057 Zürich, Switzerland.
Laura KunzFunctional Genomics Center Zürich, ETH Zürich/University of Zurich, 8057 Zürich, Switzerland.
Witold WolskiFunctional Genomics Center Zürich, ETH Zürich/University of Zurich, 8057 Zürich, Switzerland.
Zahra MotamedInstitute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, 8057 Zürich, Switzerland.
Daniela MeierZyto/Histo Diagnostik Labor Freienstein, 8427 Freienstein, Switzerland.
Franco GuscettiInstitute of Veterinary Pathology Vetsuisse Faculty, University of Zurich, 8057 Zürich, Switzerland.
Mirja C NolffSmall Animal Surgery, Tierspital Zürich, 8057 Zürich, Switzerland. Electronic address: mirjachristine.nolff@uzh.ch.
Enni MarkkanenInstitute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, 8057 Zürich, Switzerland. Electronic address: enni.markkanen@vetpharm.uzh.ch.
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrosarcoma (FSA) are rare soft tissue tumors that display aggressive local behavior and invasive growth leading to high rates of tumor recurrence. While the low incidence in humans hampers detailed understanding of the disease, FSA are frequent in dogs and present potential models for the human condition. However, a lack of in-depth molecular characterization of FSA and unaffected peritumoral tissue (PTT) in both species impedes the translational potential of dogs. To address this shortcoming, we characterized canine FSA and matched skeletal muscle, adipose and connective tissue using laser-capture microdissection (LCM) and LC-MS/MS in 30 formalin-fixed paraffin embedded (FFPE) specimens. Principal component analysis of 3'530 different proteins detected across all samples clearly separates the four tissues, with several targets strongly differentiating tumor from all three PTTs. 25 proteins were exclusively found in tumor tissue in ≥80% of cases. Among these, CD68 (a macrophage marker), Optineurin (OPTN), Nuclear receptor coactivator 5 (NCOA5), RAP1GDS1 (Rap1 GTPase-GDP dissociation stimulator 1) and Stromal cell derived factor 2 like 1 (SDF2L1) were present in ≥90% of FSA. Protein expression across all FSA was highly homogeneous and characterized by MYC and TP53 signaling, hyperactive EIF2 and immune-related changes as well as strongly decreased oxidative phosphorylation and oxidative lipid metabolism. Finally, we demonstrate significant molecular homology between canine FSA and human soft-tissue sarcomas, emphasizing the relevance of studying canine FSA as a model for human FSA. In conclusion, we provide the first detailed overview of proteomic changes in FSA and surrounding PTT with relevance for the human disease.

Indexed as

FibrosarcomaProteomicsAnimalsChromatography, LiquidDogsHumansNeoplasm Recurrence, LocalTandem Mass Spectrometryadult-type fibrosarcoma not otherwise specifiedComparative oncologydog fibrosarcomaFibrosarcoma characterizationHuman fibrosarcomaLaser-capture microdissectionrare cancersSoft-tissue sarcoma

Identifiers

PMID36508875
PMCPMC9761855
OpenAlexW4311769695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.